课题基金 / 基金详情

Interdisciplinary training in pharmacological sciences

Interdisciplinary training in pharmacological sciences
药理学科学跨学科培训
批准号:
10612467
负责人:
Sean Edward Lawler
金额:
$21.22万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-07-01 至 2026-06-30

项目摘要

项目成果

Sean Edward Lawler的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The Graduate Program in Molecular Pharmacology & Physiology is a small and very diverse program with a strong set of courses and activities, as well as extensive mentoring mechanisms. Leadership of the program is by a group of three accomplished MPIs with complementary strengths and expertise that guarantee effective oversight of the program. The request is for 4 T32 slots per year; the total number of students in the program is 20. This training program in "Interdisciplinary Training in Pharmacological Sciences" will replace our current NIGMS pharmacology T32, ending in June of 2021. The training in our program focuses on fundamental principles of pharmacology, rigor and reproducibility, and cutting-edge quantitative methods. Our trainees participate in many activities that promote interaction, collaboration and professional development. Here we propose a number of new initiatives in the curriculum, professional development, program oversight and recruitment. A recent innovative initiative we are developing in the program is the establishment of summer internships at Pfizer pharmaceutical company labs; these internships will give our trainees the unique opportunity to experience first-hand the scientific environment in a pharmaceutical company and make informed decisions for their future careers. Our current admissions and recruitment practices have yielded a high percentage of students from disadvantaged and underrepresented groups (in the last 5 years, 47% underrepresented minorities plus 7% disabled), and there has been 100% retention of these students in the program during the last 15 years (retention for the program in general is 95%). The career outcomes of the students are excellent, with 52% of students staying in academia (25% faculty, 27% currently postdocs) often at top institutions, about 25% as scientists in pharmaceutical or biotechnology companies, and the remainder in a variety of science and medicine- related careers. Thus, our program has been training a highly diverse group of students who have become successful in different areas of science; the new initiatives proposed in our T32 application will further enhance our unique program and improve the quality of the training.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
Identification and characterization of MAM03055A: A novel bivalent sigma-2 receptor/TMEM97 ligand with cytotoxic activity.
MAM03055A的鉴定和表征:具有细胞毒性活性的新型二价Sigma-2受体/TMEM97配体。
DOI: 10.1016/j.ejphar.2021.174263
发表时间: 2021-09-05
期刊: European journal of pharmacology
影响因子: 5
作者: [Liu CZ, Mottinelli M, Nicholson HE, McVeigh BM, Wong NK, McCurdy CR, Bowen WD]
通讯作者: Bowen WD
DOI: 10.1063/5.0128815
发表时间: 2022-12
期刊: The Journal of chemical physics
影响因子: --
作者: [Helen B. Belato;C. Norbrun;Jinping Luo;Chinmai Pindi;Souvik Sinha;Alexandra M. D’Ordine;G. Jogl;G. Palermo;George P. Lisi]
通讯作者: Helen B. Belato;C. Norbrun;Jinping Luo;Chinmai Pindi;Souvik Sinha;Alexandra M. D’Ordine;G. Jogl;G. Palermo;George P. Lisi
DOI: 10.1172/jci.insight.159578
发表时间: 2022-09-22
期刊: JCI INSIGHT
影响因子: 8
作者: [Sun, Xiuna, Nakajima, Erika, Norbrun, Carmelissa, Sorkhdini, Parand, Yang, Alina Xiaoyu, Yang, Dongqin, Ventetuolo, Corey E., Braza, Julie, Vang, Alexander, Aliotta, Jason, Banerjee, Debasree, Pereira, Mandy, Baird, Grayson, Lu, Qing, Harrington, Elizabeth O., Rounds, Sharon, Lee, Chun Geun, Yao, Hongwei, Choudhary, Gaurav, Klinger, James R., Zhou, Yang]
通讯作者: Zhou, Yang
Preclinical assessment of efficacy and tumor microenvironment alterations by PPRX-1701 in glioblastoma
  • 批准号:
    10578085
  • 项目类别:
  • 资助金额:
    $22.95万
  • 财政年份:
    2023
  • 负责人:
    Sean Edward Lawler
  • 依托单位:
Interdisciplinary training in pharmacological sciences
  • 批准号:
    10402758
  • 项目类别:
  • 资助金额:
    $20.81万
  • 财政年份:
    2021
  • 负责人:
    Sean Edward Lawler
  • 依托单位:
Fluorinated macrocyclic peptides as BBB penetrating agent for improved GBM treatment
  • 批准号:
    10189534
  • 项目类别:
  • 资助金额:
    $27.61万
  • 财政年份:
    2019
  • 负责人:
    Sean Edward Lawler
  • 依托单位:
Fluorinated macrocyclic peptides as BBB penetrating agent for improved GBM treatment
  • 批准号:
    10442440
  • 项目类别:
  • 资助金额:
    $51.64万
  • 财政年份:
    2019
  • 负责人:
    Sean Edward Lawler
  • 依托单位:
海外基金